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Concussion is the most common form of mild traumatic brain injury (mTBI). Although
most patients’ symptoms resolve within a month, patients with post-concussion
syndrome (PCS) may continue to experience symptoms for years and have limited
treatment options. This pilot study assessed the feasibility and symptom-related effects
of a ketogenic diet (KD) in patients with PCS symptoms. The Ketogenic Diet in
Post-Concussion Syndrome (KD-PCS) was a single-arm trial of a 2-month KD high in
non-starchy vegetables and supplemented with medium-chain triglyceride (MCT) oil.
Macronutrient targets were≥70% fat,≤10% carbohydrate, and the remainder as protein
as energy. We assessed feasibility by daily self-reported measure of urine acetoacetate
and collection of 3-day food records and serum beta-hydroxybutyrate at multiple
timepoints. We assessed symptoms by administering the Immediate Post-Concussion
Assessment and Cognitive Testing (ImPACT) and Modified Balance Error Scoring System
(M-BESS) at baseline and month 2 and the Post-Concussion Symptom Scale (PCSS)
at baseline, month 1, and month 2. Fourteen participants enrolled in the KD-PCS.
Twelve participants completed the study and 11 implemented the KD (73% fat, 9%
carbohydrate, and 18% protein) and achieved ketosis. One participant complained of
MCT-related diarrhea that resolved and another reported nausea and fatigue that resulted
in withdrawal from the study. Among compliant participants, the visual memory domain of
the ImPACT improved by 12 points (p = 0.02) and PCSS scores improved by 9 points,
although not statistically significant. This pilot trial suggests that the KD is a feasible
experimental treatment for PCS and justifies further study of its efficacy.
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INTRODUCTION
Concussions are the leading form of mild traumatic brain injury (mTBI). The CDC reported the
U.S. population sustains 1.7 million concussions annually and, although underreported by as much
as 80%, the annual rate of concussion has more than doubled in the past decade (1). Evidence-based
clinical management of concussions, therefore, is of particular relevance. While 90% of
patients have resolution of symptoms within 4 weeks, the remainder experience persistent and
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oftentimes debilitating symptoms for months or even years
(2), a condition termed post-concussion syndrome (PCS) (3).
Unresolved cognitive or memory problems can significantly
limit daily activities and have potentially neurodegenerative
consequences later in life (4). Currently, treatment is aimed at
symptoms but rarely addresses the underlying injury. This is an
important limitation in treating post-concussion syndrome and
can lead to prolonged recovery periods.
The brain is a highly metabolic organ that requires
substantial and uninterrupted energy, usually supplied by
glucose. Glucose uptake is severely diminished in the metabolic
cascade that occurs after a concussion injury (5), resulting
in a condition of brain hypometabolism that can persist for
months (6). Correction of this bioenergetic deficit may serve
as a potential therapeutic target for underlying post-concussive
symptoms. One such approach, the high fat, carbohydrate
restricted ketogenic diet (KD), reduces reliance upon glucose
metabolism in favor of metabolism of ketones, the body’s
alternative energy substrate. Ketones contribute significantly to
cerebral metabolism (7–9) which, perhaps most importantly,
appears to remain intact in conditions with impaired glucose
metabolism (10–12).
The KD is used effectively for children with intractable
seizures (13–16) and has gained significant interest as a
possible therapeutic approach in other neurological conditions
with a growing number of studies demonstrating a potential
neuroprotective role (17–20). Our recent data also suggests
that the KD offers symptomatic benefit in patients with
Alzheimer’s disease (AD) (21), a condition with a similar
observance of hypometabolism due to decreased brain glucose
consumption (22, 23). In AD, it is suggested that raising
levels of serum beta-hydroxybutyrate (BHB), the primary
circulating ketone body, to 0.5 mmol/L is sufficient to bolster
brain metabolism (24). KDs and circulating ketones also have
purported signaling properties (25), reduce oxidative stress (17,
26, 27), decrease systemic inflammation (28), and promote
mitochondrial function (29). In animal TBI models, ketosis-
inducing nutritional approaches have been demonstrated to have
neuroprotective benefit (30–35) and promising improvement
in cognition and behavior (31, 32). Acutely post-TBI, cerebral
ketone concentration is elevated and can be modulated through
administration of ketosis-inducing nutrition (36). Elevated
cerebral ketone concentration could be indicative of a metabolic
adaptation to ketone metabolism in the early stages of
TBI. Given the existing mechanistic evidence, human clinical
investigation into the KD’s potential as a therapy in TBI
is warranted.
The primary purpose of the present study was to
establish feasibility of implementing an 8-week KD in
patients with PCS symptoms. Our secondary aims were to
assess changes in cognition and self-reported symptoms
coincident with the KD treatment. We hypothesized
that patients would be compliant with the 8-week KD
protocol, identified by monitor of dietary intake and
two measures of ketosis, and that compliant participants
would experience improvement in cognitive performance
and symptomology.
METHODS
The Ketogenic Diet in Post-Concussion Syndrome (KD-PCS)
was a single-arm, pilot clinical study with a target enrollment of
14 subjects with Post-Concussion Syndrome (PCS). The protocol
required participants to maintain an MCT supplemented KD for
8 weeks. The KD was isocaloric and increased dietary fat to offset
decreased carbohydrate consumption, thus we refer to our diet
as a very high-fat KD (VHF-KD) to distinguish our diet from a
calorie-restricted, low carbohydrate KD.
We prospectively recruited participants from The Center for
Concussion Management clinics in the Neurology and Trauma
Surgery Departments at The University of Kansas Health System.
Participants
Participants all had PCS defined as having suffered a concussion
resulting from a direct blow, rotation, or whiplash injury to the
head or body. The subjects had to be at least 4 weeks post-injury
when recruited and have persistent symptoms that included
cognitive problems (slowed processing, fogginess, confusion,
impaired short-term memory, limited attention span, poor
problem solving) as assessed by self-report, clinical observation,
or neurocognitive testing. Individuals were required to have a
body mass index (BMI) of >21 kg/m2 and have mastery of the
English language. Only patients between the ages of 18–65 years
old were considered for participation. A complete metabolic
panel which included electrolytes, liver function tests (LFTs), and
blood glucose levels, hematology, insulin, beta-hydroxybutyrate,
and cholesterol levels were collected and reviewed after consent
but resulting lab values did not determine eligibility. Exclusion
criteria included serious medical risks such as insulin dependent
diabetes mellitus, ongoing cancer, or recent vascular event (i.e.,
stroke, heart attack, angioplasty, etc.), neurologic conditions
other thanmTBI (including cognitive dysfunction), consumption
of greater than two alcoholic drinks per day (as determined by
patients’ self-report), and individuals involved in a lawsuit related
to their injury (37). The KUMedical Center’s Institutional Review
Board approved the protocol. Informed consent was obtained
from all study participants as per institutional guidelines.
Dietary Intervention
Participants received nutrition counseling from the study
registered dietitian (RD) at the baseline study visit. They were
counseled to consume a self-selected, 1:1 ratio (ratio of grams
of lipid to grams of non-lipid) VHF-KD in which energy
was derived of 5–10% carbohydrate, 70–75% fat, and 20–25%
protein. Dietary principles of the VHF-KD have been previously
described (38) and are presented in Table 1. Participants were
encouraged to consume a medium chain triglyceride (MCT) oil
(NOWFoods, USA) containing a combination of C8:0 and C10:0
fatty acids. To promote MCT oil tolerance, dosage started at 1/2
tablespoon/day for the first week and increased by 1/2 tablespoon
weekly until reaching a goal of 1–2 tablespoons/day based on
individual tolerance. Energy needs were determined using the
Mifflin-St Jeor equation (39). Weight loss was discouraged in
this study, thus energy needs were adjusted as needed during the
intervention to prevent excessive weight loss among participants.
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TABLE 1 | KD-PCS ketogenic diet education principles.
Component Guidelines
Macronutrient
Fat Consume at least 70% as energy
Focus: extra virgin olive oil, avocado, olives, nuts and seeds
Moderate: nut and seed butters, butter, bacon
Carbohydrate Restrict to 10% of energy or less
Primarily comprised of non-starchy vegetables
Protein Not to exceed 100 g for most individuals




MCT oil Titrate dosage weekly by 1/2 tablespoon starting at 1/2
tablespoon per day
Aim for 1–2 tablespoons daily, as tolerated
Best tolerated in coffee and blended with additional
long-chain fat source
Vegetables Unlimited intake of non-starchy vegetables
Eliminate starchy vegetables
Add fat prior to and after cooking vegetables
Fruit Restrict to 1/4–1/2 cup of berries per day
Unlimited avocado intake
Dairy Heavy cream as an additive to coffee or tea
1-2 servings of full fat cheese allowable
Limit unsweetened, full fat milk or yogurt to no more than 1/2
cup daily
Grains Eliminate refined and whole grains
Replace grain flours with almond or coconut flour
Sweetener Eliminate sugar intake
Use sweeteners sparingly, primarily Stevia or Truvia
Water Drink at least 64 fluid ounces of water daily
General
Supplementation Multivitamin (not included in this analysis)
Urinary ketones Measure and record urinary ketones daily
If not producing ketones, reduce carbohydrate, and
increase fat
Provided materials included a VHF-KD diet manual containing
a description of dietary principles and sample recipes, a 2-month
supply of MCT oil, and a daily multivitamin (Kirkland Signature,
USA) to address potential micronutrient deficiency concerns.
Dietary Assessment
Dietary intake was measured using 3-day food records (3DFR).
The study RD provided written and verbal instructions to
participants to complete the 3DFR. Dietary intake was recorded
in real time and included 2 weekdays and 1 weekend day at
baseline, month 1, and month 2. The RD reviewed completed
food records with participants at study visits to ensure
completeness and address detail clarifications. Baseline 3DFR
reflected dietary intake prior to initiation of the VHF-KD while
3DFR from month 1 and month 2 reflected intake during the
VHF-KD intervention. Food record data were entered into the
Nutrition Data System for Research (NDSR) 2016 to quantify
food and nutrient intake.
Biomarker, Safety, and Anthropometric
Assessments
Participants self-monitored urine ketones daily, in the early
evening, using urine acetoacetate test strips (Ketostix, Bayer,
Germany). Daily urine ketone status was recorded as either
negative, trace (5–14.9 mg/dL), small (15–39.9 mg/dL), moderate
(40–79.9 mg/dL), or large (80+mg/dL) in a provided diary. Days
in which participants did not measure the ketone levels were
conservatively tallied as a “negative” ketone response.
All serum biomarker and lab tests were collected after a 12-h
fast. Full lipid, hematology, and metabolic panels were collected
at the baseline and month 2 (end of diet intervention) visits, and
these assays were performed by the Quest Diagnostics clinical
laboratory. Serum beta-hydroxybutyrate (BHB) and insulin levels
were measured at all visit time points (baseline, month 1, and
month 2) by Quest Diagnostics clinical laboratory. Homeostatic
model assessment 2-insulin resistance (HOMA2-IR) values for
each participant were calculated using a HOMA2 Calculator (v.
2.2.3; University of Oxford, United Kingdom).
Height and weight were measured for all subjects. BMI
(kg/m2) was calculated using weight and height measurements.
Dietary Obstacles and Palatability
Participants completed short questionnaires upon study exit.
These questionnaires were designed to identify obstacles
encountered during the VHF-KD as well as the palatability and
pleasure of the food items consumed while on the VHF-KD.
Cognitive Testing
We assessed cognitive performance utilizing the Immediate Post-
Concussion Assessment and Cognitive Testing (ImPACT). The
ImPACT test was administered at the study baseline visit as well
as at the month 2 visit.
Symptom Evaluation
Participants completed a Post-Concussion Symptom Scale
(PCSS) checklist at all three study visits. The PCSS is a self-
reported assessment of 22 symptoms using a Likert-type scale
ranging from 0 to 6, with 0 indicating no difficulty with the
outlined symptom and ratings of 1–6 representingmild-to-severe
difficulty with the symptom. The PCSS is part of the ImPACT
computerized testing and was conducted with the ImPACT test
at baseline and month 2 visits. A paper version of the PCSS
was completed by the subject at all three study visits. We also
assessed depression and anxiety symptoms at baseline and at
the study conclusion. To assess severity of depression symptoms,
participants completed the Patient Health Questionnaire (PHQ-
9). The PHQ-9 is a 9-question survey that asks questions about
depression symptoms over the previous 2 weeks (40). Each
question is scored 0–3 and summed to form a maximum score
of 27 with higher scores relating to more severe depression
symptoms. We assessed anxiety symptoms using the General
Anxiety Disorder (GAD-7) questionnaire, a 7-question, self-
reported anxiety survey that has been validated for the general
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population (41). Each question is scored 0–3 and summed to
form a maximum score of 21 with higher scores relating to more
severe anxiety.
Balance Testing
The Modified Balance Error Scoring System (M-BESS) (42) was
completed at the baseline and month 2 visits. The M-BESS tests
an individual’s postural stability on a firm, flat surface in three
different stances: double-leg, single-leg, and tandem gait. The test
is performed barefoot with eyes closed and hands placed on the
hips. Each stance has a maximum score of 10 and 1 point is
subtracted for each mistake. Total M-BESS scores are calculated
by summing the scores of each stance.
Statistical Analysis
The primary aim was to report feasibility of the VHF-KD
in patients with PCS with a secondary aim of reporting
preliminary efficacy. We report continuous data as mean ± SD
throughout, but as data were mostly non-normally distributed,
continuous variables are presented in tables as median [Q1;Q3].
We described VHF-KD feasibility using descriptive statistics
regarding compliance and study withdrawal. All data were
determined to be non-normal through the Shapiro-Wilk test
for normality and visualization of frequency histograms and
normal Q-Q plots. Owing to no missing longitudinal data
among study completers, we used the non-parametric Kruskal-
Wallis test for variance for all ANOVA models and applied the
Dunn’s Test of multiple comparisons with no adjustment for
data with values at baseline, month 1, and month 2. Statistical
analyses were performed using R (v. 3.6.1; R Foundation, Vienna,
Austria). Statistical tests were two-tailed, and significance was set
at P < 0.05.
RESULTS
Fourteen participants enrolled in the KD-PCS over a course of
18 months. Twelve participants were female and two were male
with a mean age of 45.3 ± 12.2 years (median: 51.0, IQR: 39.0–
57.5). To meet our enrollment target, we screened 283 charts
of patients that presented to the KU Health System Concussion
Clinic. The study coordinator approached 39 of these patients at
an in-person clinic visit to consider participation in this study.
Supplemental Figure 1 depicts recruitment and participant flow.
Twelve participants completed the study. Two participants
withdrew from the study after completion of the baseline study
visit—one withdrew due to complications with dietary adherence
and the other participant was lost to follow-up prior to the
month 1 visit. One participant that completed the study was not
compliant with the diet, failing to reach ketosis neither by serum
measure nor urinary measure. The remaining 11 participants
were successful at implementing the VHF-KD intervention (79%
compliance rate) by registering elevated serum BHB and urinary
ketone measures and were included in the analyses of outcomes.
Participants were not in ketosis at baseline (0.1± 0.1 mmol/L)
and significantly raised serum BHB levels at month 1 (0.5
± 0.6 mmol/L) and month 2 (0.6 ± 0.9 mmol/L), illustrated
in Figures 1A,B. Considering the 11 compliant participants,
self-reported positive urinary ketone production was recorded
a mean of 48.0 ± 13.6 days (80% of duration) during the
intervention with varying reported depth of ketosis. Of the study
duration, ketosis depth as a proportion of days in ketosis was
reported as 21% trace, 26% small, 24% moderate, and 9% large.
Blood and urinary ketone data are presented in Figure 1.
Dietary intake data from the regular diet and VHF-KD are
reported in Table 2. Energy intake was similar between the two
diets. During the intervention, total fat intake increased from 96.9
to 145.0 g (p < 0.001), total carbohydrate intake was significantly
reduced 196.5 to 42.5 g (p < 0.001), and protein intake was
similar. Participants consumed 73% of fat, 9% of carbohydrate,
and 18% of protein as a proportion of energy while on the VHF-
KD. Average consumption of MCT oil was 1.5 tbsp/day (21.5
g/day). All micronutrient intake was similar between the two
diets except for decreased thiamin and calcium intake on the
VHF-KD. Non-starchy vegetables increased from 2.1 servings to
3.1 servings on the VHF-KD (p < 0.05).
No adverse events were reported, but two minor diet-
related complaints were documented in this study. The first was
acute diarrhea in one participant after ingestion of MCT oil.
Diarrhea symptoms were alleviated by mechanically blending
MCT oil with a long-chain fatty acid (emulsification) prior to
consumption, a process purported to improve MCT tolerability
(43). One participant reported nausea and fatigue in the weeks
following VHF-KD initiation that resolved by discontinuation
of the diet. This participant discontinued the diet prior to
month 1 and withdrew from the study at that study visit. It
is notable that all participants were instructed to mechanically
blend MCT oil in beverages with an additional long-chain fat
source, primarily butter or cream, prior to ingestion. Using
this method, there was no report of common symptoms
(i.e., nausea, diarrhea, etc.) related to MCT oil tolerability.
Comprehensive labs (Table 3) were monitored throughout the
study and were unchanged.
The visual memory domain of the ImPACT assessment
improved by a mean of 12.2 points from baseline to month 2
of the intervention (59.0 ± 10.4 vs. 71.2 ± 11.1, p = 0.02).
Though not significant, mean PCSS scores improved from
baseline by 4.6 points at month 1 and 9.6 points at month 2. All
assessment results are reported inTable 4. Individual results from
the ImPACT visual memory domain and PCSS are presented
in Figure 2, stratified by the peak measured serum BHB level
achieved during the 2-month study intervention. Baseline scores
for visual memory and symptoms were highly variable. Both
scores trended toward improved scores for a majority of the
individuals except for two; one individual with no detected
ketosis via serum or urine had a slightly worsened PCSS score at
the end of the intervention and another individual who exhibited
elevated serum BHB had significantly worsened PCSS scores and
slightly worsened visual memory.
The dietary obstacles and palatability questionnaire was
completed by study finishers at the final visit and results are
reported in Table 5. Overall, participants reported that they
felt adequately trained and confident in following the VHF-
KD. No participants reported tolerance issues while following
the VHF-KD. “Strongly Disagree” was documented only once
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FIGURE 1 | Urine acetoacetate and serum BHB values among compliant participants (n = 11). (A) Serum BHB values for each subject. (B) Mean serum BHB values
± standard error. (C) The proportion of days in which each participant’s self-reported urine acetoacetate analysis revealed ketosis and depth of ketosis achieved. The
figures exclude the one participant that completed the study procedures but did not record elevated ketone bodies at any point during the intervention. *P < 0.05
compared to baseline value via Dunn’s test of multiple comparisons.
on three different statements: “I was able to calculate diet and
meals,” “The initial visit with the dietitian was sufficient for
initiation,” and “The diet was not too costly.” Four of the 12
study completers reported some level of disagreement that the
VHF-KD “was not too costly.” Five participants reported that
the VHF-KD improved their symptoms, while the remaining 7
reported that they were unsure whether the VHF-KD had any
effect on symptoms.
DISCUSSION
This is the first study to investigate whether a VHF-KD
therapy is feasible in patients with PCS, entailing a 2-month
VHF-KD with modest MCT oil supplementation. Our findings
suggest that the VHF-KD is feasible in patients suffering from
prolonged concussion-related symptoms and has coincident
relationship with improvement in visual memory and PCS-
related symptomology.
Potential participants were pre-screened and approached
during their Center for Concussion Management clinic visits.
Out of the 39 patients who expressed willingness to discuss
study participation with the study coordinator, 20 requested to
consent to enroll in the study. Six of those consenting patients
were unable to complete study enrollment and proceed with
the baseline visit, either due to personal decision or ineligibility
factors. Common recruitment barriers reported by patients to
the study coordinator included, but were not limited to, inability
or lack of desire to commit to study-related time and diet
requirements, fear of blood draws, and active litigation relating
to the concussion injury.
The diet proved feasible in 11 of 14 participants (79%
compliance) evidenced by intake of the prescribed VHF-KD
macronutrient targets and both consistent presence of urinary
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TABLE 2 | Dietary intake on the regular and ketogenic diets (n = 11)a.
Regular diet Ketogenic diet p-value
Energy/Macronutrients
Energy, kcal 1918.7 [1767.8;2213.8] 1810.5 [1675.2;1947.8] 0.25
Fat, g 95.0 [86.0;111.9] 145.4 [135.6;158.5] 0.004
% of energy 42.0 [40.5;45.0] 70.5 [66.8;76.3] 0.001
Carbohydrate, g 187.2 [166.6;230.4] 42.1 [32.8;51.6] 0.001
% of energy 37.4 [33.4;43.0] 8.3 [7.0;9.5] 0.001
Protein 75.3 [65.0;81.2] 80.3 [65.5;100.6] 0.64
% of energy 13.4 [12.6;15.9] 19.9 [16.3;21.5] 0.13
Fatty acid composition
MCT Oil, g 0.0 ± 0.0 21.5 ± 6.5 <0.001
SFA, g 32.8 [29.2;39.6] 68.1 [65.0;80.0] 0.003
MUFA, g 33.8 [33.0;44.3] 44.5 [42.2;48.1] 0.13
PUFA, g 20.5 [17.3;21.1] 14.7 [12.0;19.9] 0.36
Trans fatty acids,
g
2.1 [1.8;2.8] 3.1 [1.7;3.4] 0.56
Eicosapentanoic
acid, g
<0.1 [<0.1;<0.1] <0.1 [<0.1;0.2] 0.20
Docosahexanoic
acid, g
<0.1 [<0.1;0.1] 0.1 [<0.1;0.4] 0.09
Cholesterol, mg 363.6 [284.0;497.8] 666.2 [497.1;754.4] 0.02
Carbohydrate
Sugar, g 78.2 [68.3;100.0] 13.8 [12.7;21.8] 0.002
Total fiber, g 16.8 [13.4;20.1] 11.1 [8.6;15.0] 0.04
Soluble fiber, g 5.5 [5.0;6.5] 3.2 [1.7;5.1] 0.03
Insoluble fiber, g 9.7 [8.2;14.3] 8.1 [6.6;9.9] 0.17
Decreased micronutrients
Thiamin, mg 1.5 [1.2;1.6] 0.6 [0.5;1.0] 0.004
Calcium, mg 773.9 [749.9;969.5] 515.7 [440.0;595.0] 0.003
Fruits and vegetablesb
Fruit 0.6 [0.1;1.2] 0.2 [0.0;0.3] 0.16
Avocados 0.0 [0.0;0.0] 0.1 [0.0;0.6] 0.13
Non-starchy
vegetables
2.0 [1.6;2.4] 2.7 [2.5;3.3] 0.02
aValues are median [Q1;Q3]. Group differences were assessed by the Kruskal–Wallis test
for variance. Significance was set at P < 0.05. All dietary data were derived by 3-d food
record at each time point. For both diets, nutrient data were derived by food only. MCT,
medium-chain triglyceride; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated
fatty acid; SFA, saturated fatty acid.
bFruit and vegetable intake reported as 1/2-cup raw servings and 1-cup cooked servings.
ketones and elevated blood ketones. Self-reported presence of
urinary ketones exceeded our expectations. Eight of the 11
compliant participants reported a frequency of >80% of days in
ketosis. During the VHF-KD education portion of the baseline
visit, participants were encouraged to achieve a goal of small
to moderate ketosis. Ten participants met that goal and 7
exceeded the goal by reporting achievement of large ketosis. It
is notable that MCT oil (1.5 tbsp/day) was primarily consumed
in the morning with coffee and urine ketone testing occurred
in the evening, effectively reducing the potential for artificially
large ketosis measurement due to acute MCT-induced elevation
in circulating ketones and adequately reflected the ketogenic
capacity of the overall diet. Seven of the eleven participants
presented with fasted serum BHB levels ≥0.5mM at a minimum
of one of the two study visits concurrent with the VHF-KD
intervention. At the month 1 visit, 3 participants with BHB
levels <0.3mM reported having deviated from the VHF-KD
in the previous few days due to personal circumstances, such
as celebratory events or stress. These events may have affected
the potential serum BHB results from this study and suggests a
need to incorporate additional blood biomarker measurement in
future studies.
Illustrated in Figure 1, participant 9 appeared to have only
recorded urine acetoacetate for∼25% of the intervention and did
not provide a response for urine ketonemeasurements 22% of the
intervention, which we conservatively interpreted as “negative”
readings. However, for the purpose of this feasibility study, we
did consider this participant to be compliant with the diet due
to elevated serum BHB levels at months 1 and 2 and reported
adherence to the target macronutrient composition via 3DFR.
Future KD trials should embed strategies within the study design
to encourage compliance with collection of ketosis measures to
ensure better characterization of KD compliance and determine
necessary depth and duration of ketosis for efficacy.
Participants adopted a VHF-KD with a ratio of ∼1.2:1 with
energy comprised of 73% fat and 9% carbohydrate, slightly
exceeding the 1:1 target of 70% fat and 10% carbohydrate. The
composition of the VHF-KD consumed in this study is similar in
composition to the VHF-KD we previously studied in AD (38).
Mean non-starchy vegetable intake increased one full serving
while maintaining carbohydrate restriction. We have previously
suggested that attention to diet quality may extend the putative
benefits of the KD in neurological conditions (44). Non-starchy
vegetables are an excellent source of micronutrients, are low in
energy density and carbohydrate, and should be consumed in
large quantity in a high quality KD.
We also observed improvement in the visual memory domain
of the ImPACT test and a 9-point mean improvement in self-
report of concussion-related symptoms, an improvement with
suggested clinical relevance (45). These improvements should be
interpreted with caution given that this was a single-arm study
and outcomes measures were secondary aims. Vestibular-ocular
impairment is observed post-concussion (46) andmay contribute
to deficit in visual memory, one of the most observed symptoms
in concussion patients which may persist in patients with PCS
(47, 48). Due to its consistency as a symptom post-concussion,
it is reasonable to hypothesize that the visual memory domain
may be one of the most profound to be affected by effective
therapies. Our study also complements two animal studies that
demonstrated improved cognitive function related to ketone-
inducing dietary approaches. Appelberg et al. reported that 7
days post-TBI, rats fed a KD had better improvement than
those on a regular diet in motor and cognitive function via the
Morris Water Maze task and beam walking assessment (32). This
finding was age-dependent as the improvements were observed
in rats that received head trauma 35 days post-natal and not
in rats that received head trauma 75 days post-natal; an effect
speculatively due to resilience to energy metabolism deficit and
quicker conversion to ketone metabolism in young vs. old rats
(33). The second study demonstrated that rats fasted for 24 h
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TABLE 3 | Participant characteristics and blood-derived data among compliant participants (n = 11).
Baseline Month 1 Month 2 p-value
Participant characteristics
Age 51.0 [39.0;57.5] –
Days since concussion injury 103.0 [56.0;217.5] –
Weight, kg 83.6 [70.8;95.5] 82.6 [68.3;90.2] 81.7 [68.5;89.0] 0.74
BMI 27.0 [25.6;33.5] 26.5 [24.7;31.6] 26.2 [24.5;31.2] 0.64
Blood biomarkers
Albumin, g/dL 4.4 [4.3;4.5] 4.7 [4.4;4.8] 4.5 [4.3;4.7] 0.51
Albumin/Globulin ratio 1.5 [1.4;1.8] 1.8 [1.6;1.9] 1.7 [1.6;2.0] 0.20
Alkaline phosphatase, U/L 68.0 [55.0;75.0] 55.0 [46.2;56.8] 58.0 [47.0;66.0] 0.35
ALT, U/L 19.0 [15.5;25.0] 21.0 [18.2;21.8] 19.0 [16.5;21.0] 0.62
AST, U/L 20.0 [17.5;22.5] 20.0 [18.2;21.8] 19.0 [17.0;20.0] 0.58
Calcium, mg/dL 9.8 [9.7;9.9] 9.9 [9.7;10.0] 9.8 [9.6;9.9] 0.47
Carbon dioxide, mmol/L 28.0 [25.5;28.5] 28.0 [26.0;28.8] 27.0 [25.0;29.0] 0.71
Chloride, mmol/L 102.0 [101.5;105.0] 102.0 [100.2;104.0] 104.0 [99.5;105.5] 0.73
Creatinine, mg/dL 0.8 [0.7;0.9] 0.8 [0.8;0.9] 0.8 [0.8;0.8] 0.67
eGFR, mL/min/1.73m2 86.0 [77.0;97.0] 84.5 [81.5;98.5] 87.0 [82.5;104.0] 0.67
Globulin 2.8 [2.5;3.0] 2.5 [2.4;2.9] 2.7 [2.3;2.8] 0.38
Potassium, mmol/L 4.5 [4.4;4.7] 4.3 [4.1;4.4] 4.3 [3.9;4.5] 0.31
Sodium, mmol/L 140.0 [138.5;140.0] 139.0 [139.0;140.5] 139.0 [138.5;140.5] 1.00
Total bilirubin, mg/dL 0.6 [0.5;0.8] 0.6 [0.5;0.6] 0.6 [0.4;0.8] 0.83
Total protein, g/dL 7.3 [7.0;7.5] 7.3 [6.9;7.5] 7.0 [6.8;7.4] 0.71
Urea nitrogen, mg/dL 15.0 [13.0;19.0] 14.0 [10.5;15.8] 15.0 [13.0;16.0] 0.63
White blood cell count, thousand/uL 7.0 [4.7;7.9] 6.6 [4.3;7.5] 0.69
Red blood cell count, million/uL 4.4 [4.3;4.8] 4.3 [4.2;4.5] 0.60
Hemoglobin, g/dL 13.3 [13.2;14.7] 13.4 [12.9;13.8] 0.64
Hematocrit 40.2 [39.2;44.2] 39.7 [38.6;42.1] 0.58
MCV, fL 92.7 [90.3;93.9] 91.2 [88.7;94.4] 0.92
MCH, pg 31.0 [29.6;31.5] 30.6 [30.1;31.4] 0.90
MCHC, g/dL 33.3 [33.2;33.9] 33.2 [32.6;33.7] 0.36
RDW 12.5 [11.9;13.6] 12.9 [12.2;13.1] 0.77
Platelet count, thousand/uL 287.0 [241.5;300.5] 291.0 [237.0;331.5] 0.97
MPV, fL 9.8 [9.8;10.4] 10.9 [10.0;11.1] 0.26
Absolute neutrophils, cells/uL 4350.0 [2816.5;5128.5] 4184.0 [2491.0;5209.0] 0.77
Absolute lymphocytes, cells/uL 1847.0 [1574.5;1894.0] 1754.0 [1526.0;1960.5] 0.97
Absolute monocytes, cells/uL 469.0 [346.0;530.0] 399.0 [344.0;462.0] 0.58
Absolute eosinophils, cells/uL 129.0 [106.5;146.5] 108.0 [91.5;205.0] 0.95
Absolute basophils, cells/uL 49.0 [42.5;56.5] 46.0 [42.5;52.0] 0.65
Neutrophils 65.1 [58.9;67.3] 60.0 [54.3;64.8] 0.49
Lymphocytes 25.9 [24.3;30.4] 29.1 [25.3;34.8] 0.43
Monocytes 7.0 [5.3;7.8] 6.0 [5.7;8.1] 0.84
Eosinophils 2.0 [1.4;2.5] 1.7 [1.4;3.3] 0.77
Basophils 0.7 [0.6;1.0] 0.6 [0.6;1.1] 0.89
Lipids
Total cholesterol, mg/dL 195.0 [164.5;206.5] 188.0 [175.0;208.0] 0.87
Triglycerides, mg/dL 95.0 [71.5;119.5] 102.0 [64.0;109.0] 0.87
HDL cholesterol, mg/dL 74.0 [54.5;83.5] 77.0 [53.5;95.0] 0.82
LDL cholesterol, mg/dL 96.0 [77.0;116.5] 93.0 [81.0;119.0] 0.79
Cholesterol/HDL ratio 2.6 [2.1;3.2] 2.8 [2.0;3.7] 0.92
Non-HDL cholesterol 115.0 [91.5;138.0] 114.0 [94.0;140.0] 0.92
Blood substrate biomarkers
Glucose, mg/dL 85.0 [84.0;94.5] 86.0 [82.5;90.0] 85.0 [80.0;93.0] 0.82
(Continued)
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TABLE 3 | Continued
Baseline Month 1 Month 2 p-value
Serum beta hydroxybutyrate, mmol/L 0.1 [0.1;0.2] 0.3 [0.2;0.7] 0.3 [0.1;0.6] 0.01
Insulin, uIU/mL 5.9 [3.2;11.4] 6.0 [4.1;7.4] 4.2 [3.2;8.3] 0.71
HOMA2-IR 0.8 [0.4;1.5] 0.8 [0.5;1.0] 0.7 [0.5;1.1] 0.92
Values are median [Q1;Q3]. Group differences were assessed by the Kruskal–Wallis test for variance. Significance was set at P < 0.05.
TABLE 4 | Cognition, balance, and symptom assessment among compliant
participants (n = 11).
Baseline Month 1 Month 2 p-value
ImPACT
Verbal memory 92.0 [81.5;93.5] 85.0 [81.0;88.0] 0.47
Visual memory 56.0 [51.5;66.0] 70.0 [64.5;79.5] 0.02
Visual motor
speed
30.6 [23.7;33.0] 32.9 [26.7;38.7] 0.34
Reaction time 0.9 [0.7;1.0] 0.7 [0.7;0.8] 0.22
M-BESS
Single 3.0 [0.0;4.5] 3.0 [2.0;5.0] 0.43
Double 10.0 [9.0;10.0] 10.0 [10.0;10.0] 0.48
Tandem 5.0 [2.0;7.0] 7.0 [5.0;8.5] 0.18
Total score 17.0 [11.5;20.5] 20.0 [17.5;23.0] 0.29
PCSS score 33.0 [19.5;65.5] 34.0 [17.5;56.0] 28.0 [13.5;50.0] 0.34
PHQ-9 score 16.0 [8.0;16.5] 8.0 [4.0;11.0] 0.27
GAD-7 score 10.0 [3.5;17.5] 7.0 [5.0;10.0] 0.65
Values are median [Q1;Q3]. Group differences were assessed by the Kruskal–Wallis
test for variance. Significance was set at P < 0.05. GAD-7, General Anxiety Disorder
7; ImPACT, Immediate Post-Concussion Assessment and Cognitive Testing; M-BESS,
Modified Balance Error Scoring System; PCSS, Post-Concussion Symptom Scale; PHQ-
9, Patient Health Questionnaire 9.
immediately post-concussion had elevated ketone bodies at 24 h,
performed better on the Morris Water Maze task at 10 days, and
had more cortical tissue at 15 days (31). Other studies suggest
that acutely post-TBI, adolescent rats fed a KD have improved
cortical contusion volume 1 week post-injury (49) and reduced
anxiety and depression symptoms (50).
PCS is still not well-understood. The condition itself is defined
by concussion-related symptoms that persist beyond the course
of normal concussion recovery, commonly persisting beyond
improvement of physiological biomarkers of existence of mTBI
(3). Acutely after mTBI, cerebral perfusion (51–53) and glucose
metabolism become impaired (54). This hypometabolic state is
typically corrected within a few days to a week; however, limited
evidence suggests chronic impairment of these mechanisms
as a compelling explanation for sustained symptoms. Under
normal conditions, cerebral blood flow (CBF) is coupled with the
cerebral metabolic rate of glucose to meet brain energy demand.
Immediately following mTBI, CBF decreases (55) followed by
hyperemia and later uncoupling of CBF and cerebral metabolism
(56) that persists in those with PCS (57). The metabolic
implications of this cascade leading to chronic reduction in brain
glucose metabolism may be an underlying cause of symptoms in
patients with PCS (58). If so, PCS shares a similar hallmark with
AD (59), a condition in which ketone metabolism mechanisms
and potential therapeutic value of the KD have recently been
studied with some extensity (10, 21, 24, 60). It is possible
that AD and PCS share the common thread of underlying
cerebral glucose hypometabolism, potentially rescuable through
exchanging glucose metabolism in favor of ketone bodies and
its downstream metabolic effects (28). We are unable to assess
mechanisms through which the KD may influence cognition or
symptom change in this study.
We also consider other mechanisms by which the KD
and ketone bodies, independently, may be beneficial in PCS
(44). Ketone body metabolism is suggested to produce fewer
reactive oxygen species (ROS) than glucose metabolism and
KDs, specifically, have been shown to upregulate mitochondrial
antioxidant systems that scavenge ROS. Reduction in ROS
activity may reduce ROS-related mitochondrial damage
and preserve mitochondrial function. In a ketotic state,
mitochondrial uncoupling proteins (UCP) are upregulated,
enhancing energy production derived by the electron transport
chain (ETC). Evidence also suggests that the KD upregulates the
anti-inflammatory pathway, nuclear factor-E2 (Nrf2). Through
both direct effects and preserved mitochondrial function,
KDs and ketone bodies may also improve regulation of brain
neurotransmitter levels. Considering the evidence for KDs and
ketone bodies, it would be desirable to know whether potential
benefit in patients with PCS would require adherence to the
KD or if other ketone-generating approaches, such as MCT or
exogenous BHB supplements alone, are sufficient.
Our group’s previous success with implementing the VHF-
KD in an AD clinical trial (21) provided preliminary experience
with and adaptability to the potential challenges faced at both the
individual and systemic level in this study. The diet education
provided to participants in this study was refined from the
previous AD study to portray a simple message and empower
participants to follow a VHF-KD that fit their food preferences
and proficiency for food preparation. In addition to a 3-day
sample menu adjusted to each participant’s energy needs, we
provided nearly 100 KD-friendly recipes with variable time
allocation and skill requirement along with recommended recipe
resources. Through this process, we’ve found that one of the
simplest guides for success with the KD is to use Ketostix
readings as an immediate feedback mechanism; if no ketone
presence is detected, then the participant’s actionable step, using
the principles of a well-formulated KD, is to simply consume
additional fat and further restrict carbohydrate the following
day. Contrasting the participants from this study with the
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FIGURE 2 | Individual change in symptom and visual memory scores among all completing participants (n = 12). (A) The individual change in the post-concussion
symptom scale (PCSS) from baseline to 2 months. Decreasing scores indicate improvement in self-reported symptoms. (B) The individual change in ImPACT visual
memory scores from baseline to 2 months. Increasing scores indicate improvement in tested visual memory. Serum ketosis levels were determined by peak measured
serum BHB. Different line types indicate the month which peak ketosis was reached, a solid line indicating both month 1 and 2, a dashed line indicating month 1, and
a dotted line indicating month 2. One participant (*) was considered not compliant with the KD and did not produce urine ketones as indicated by the urine ketone
record nor had elevated serum BHB at any study visits. This participant’s symptom score slightly worsened and verbal memory score slightly improved from at the end
of the study. The other two participants that did not register elevated BHB at study visits recorded trace ketone production via urine ketone records during the course
of the study.
TABLE 5 | Dietary obstacles and palatability among study completers (n = 12).
Strongly agree Agree Neutral/Unsure Disagree Strongly disagree
I was able to calculate diet and meals 2 (17%) 6 (50%) 3 (25%) 0 (0%) 1 (8%)
I was able to follow the diet 6 (50%) 5 (42%) 0 (0%) 1 (8%) 0 (0%)
I tolerated the diet 8 (67%) 2 (17%) 2 (17%) 0 (0%) 0 (0%)
The diet improved symptoms 2 (17%) 3 (25%) 7 (58%) 0 (0%) 0 (0%)
I felt adequately trained on the diet 6 (50%) 3 (25%) 1 (8%) 2 (17%) 0 (0%)
The initial visit with the dietitian was sufficient for initiation 9 (75%) 1 (8%) 1 (8%) 0 (0%) 1 (8%)
Follow up with dietitian was adequate 8 (67%) 4 (33%) 0 (0%) 0 (0%) 0 (0%)
I was able to maintain normal activity 10 (83%) 2 (17%) 0 (0%) 0 (0%) 0 (0%)
The diet was not too costly 5 (42%) 3 (25%) 0 (0%) 3 (25%) 1 (8%)
Overall, I was satisfied with the diet 8 (67%) 3 (25%) 1 (8%) 0 (0%) 0 (0%)
Values are n (%).
previous AD study, compliance is likely more attainable due
to patient independence without the need of a study partner
and the associated burden for a study partner to implement
the diet. On the other hand, some participants in this study
required a significant level of contact with the study team to
remain compliant with the KD, seemingly due tomemory-related
symptoms suffered from the patient’s concussion.
The KD is most well-known as an effective treatment
in refractory epilepsy (13–16). It is important, however, to
distinguish the KD used for treatment of epilepsy and other
conditions in which the KD may also be valuable as a treatment.
Patients with epilepsy use the KD to maintain seizure control
and it has been suggested that, in some cases, serum BHB
levels must reach ≥4.0 mmol/L for this benefit (61). The
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KDs in these particular circumstances are strict and require
carbohydrate restriction of ≤2% of energy and consumption
of ≥90% of fat as energy (44). Compliance with a diet of
this macronutrient distribution within free-living adults with
a condition of brain bioenergetic disruption is likely not
feasible, nor necessary. Patients with AD improve overall cerebral
metabolic rate with modest ketosis approaching 0.5 mmol/L
(24). If these mechanisms overlap, we hypothesize that the
majority of our participants raised their serum BHB to a level
that may have been sufficient to contribute as a substrate for
brain metabolism.
We also acknowledge limitations that reduce our ability to
interpret feasibility and outcomes in this study. Participants
performed daily self-monitoring of ketosis by urine acetoacetate
strips, which presents two limitations. First, self-report is subject
to inaccurate reporting by the participant. Second, although urine
acetoacetate measurement is positively associated with blood-
derived measurement of ketosis (62), capillary measurement of
BHB by fingerstick is a more sensitive measure of circulating
ketones and should be considered as a measurement in future
KD trials. We also assessed serum BHB levels in the morning
after a 12 h fast at only two time points during the intervention.
From this limited assessment, we are unable to elucidate whether
serum BHB levels may have been highest at this point due to a
fasting effect, or whether serum BHB levels may have been higher
after consuming the KD due to consumption of fat substrate
for ketogenesis. The direction of post-prandial BHB response
is influenced by compliance to the KD macronutrient profile.
Measurement of capillary BHB at multiple, varying timepoints
would provide better insight for characterization of dietary
compliance and general ketone status. Finally, this is a small
pilot study that aimed to test feasibility of the KD in individuals
with PCS. Lacking a control group, we encourage caution in
interpreting the results of this study as we are unable to determine
if coincident changes in cognition and reported symptoms were
due to the KD intervention.
The KD-PCS was designed to assess feasibility of a VHF-KD
in patients with PCS and confirms that adherence to a VHF-
KD in this population is feasible. Due to the small sample size
and single-arm design of the study, we are unable to conclude
that the VHF-KD was responsible for observed improvement
in visual memory or report of symptoms. We urge caution in
interpreting our coincidental findings. However, the results from
this study do suggest potential for the KD to benefit patients
with prolonged symptoms due to concussion and warrants future
studies to investigate the KD as a potential therapeutic approach.
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